Withus Pharmaceutical KRX:330350KOSDAQ
위더스제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, Withus Pharmaceutical reported revenue of ₩29.1bn, up 10.8% year on year, and operating profit of ₩1.1bn. Withus Pharmaceutical (위더스제약) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 1 article.
Withus Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩29.1bn | +10.8% | ₩1.1bn margin 3.7% | ₩2.0bn |
| Q1 2026 | ₩28.2bn | +9.5% | ₩244m margin 0.9% | ₩4.0bn |
| Q4 2025 derived | ₩27.2bn | +19.0% | ₩1.4bn margin 5.1% | −₩120m |
| Q3 2025 | ₩27.3bn | -1.4% | ₩1.4bn margin 5.0% | ₩2.1bn |
| Q2 2025 | ₩26.2bn | -0.0% | ₩831m margin 3.2% | ₩1.3bn |
| Q1 2025 | ₩25.8bn | -0.8% | ₩2.1bn margin 8.1% | ₩1.6bn |
| Q4 2024 derived | ₩22.8bn | -11.7% | ₩565m margin 2.5% | ₩1.2bn |
| Q3 2024 | ₩27.6bn | +37.0% | ₩2.0bn margin 7.3% | ₩1.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Withus Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2